Barriers to hepatitis C treatment (Q27012664)

Michael W. Fried

series ordinal

2

1 reference

language of work or name

1 reference

February 2012

1 reference

1 reference

32 Suppl 1

1 reference

page(s)

151-6

1 reference

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

Outcomes of treatment for hepatitis C virus infection by primary care providers

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

Variation in hepatitis C services may lead to inequity of heath-care provision: a survey of the organisation and delivery of services in the United Kingdom

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

Telaprevir for previously untreated chronic hepatitis C virus infection

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

Boceprevir for untreated chronic HCV genotype 1 infection

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

Diagnosis, management, and treatment of hepatitis C: an update

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

Barriers to accessing care in patients with chronic hepatitis C: the impact of depression

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

Hepatitis C treatment completion rates in routine clinical care

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

Hepatitis C treatment for injection drug users: a review of the available evidence

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

Limited uptake of hepatitis C treatment among injection drug users

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

Outcomes of a Hepatitis C screening program at a large urban VA medical center

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

Barriers to the treatment of hepatitis C. Patient, provider, and system factors

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

Management of patients with hepatitis C in a community population: diagnosis, discussions, and decisions to treat

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

Hepatitis C virus-infected patients report communication problems with physicians

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

"They treated me like a leper". Stigmatization and the quality of life of patients with hepatitis C.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

Screening and counseling practices reported by obstetrician-gynecologists for patients with hepatitis C virus infection

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

Side effects of therapy for chronic hepatitis C.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

Limited success of HCV antiviral therapy in United States veterans

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

Injecting drug users' understanding of hepatitis C.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

Surprisingly small effect of antiviral treatment in patients with hepatitis C.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

A balancing view: We cannot do it alone

31 May 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02706.X

Market uptake of new antiviral drugs for the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02706.X

The impact of the prevention programme of hepatitis C over more than a decade: the French experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02706.X

The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02706.X

Institute of Medicine recommendations for the prevention and control of hepatitis B and C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02706.X

Survey of hepatitis B and C in addiction treatment unit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02706.X

Reasons for non-treatment of hepatitis C in veterans in care

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02706.X

High rates of uninsured among HCV-positive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02706.X

What do patients consider when making decisions about treatment for hepatitis C?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02706.X

Social stigmatization and hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02706.X

Psychiatric disorders among veterans with hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02706.X

High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02706.X

Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02706.X

Treatment of chronic hepatitis C in active drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02706.X

Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02706.X

Treatment of hepatitis C infection in injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02706.X

A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02706.X

Management of hepatitis C patients by primary care physicians in the USA: results of a national survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02706.X

Hepatitis C knowledge among staff in U.S. drug treatment programs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02706.X

Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02706.X

Family physicians' knowledge and screening of chronic hepatitis and liver cancer.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

Identification and management of hepatitis C patients in primary care clinics

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3955982

Serologic findings with hepatitis B in hemophilia

28 November 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/22212587

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Patients with hepatitis C are best managed by a specialist in liver diseases. CON: The management of hepatitis C in a community-based practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/22212587

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/J.1478-3231.2011.02706.X

1 reference

1 reference

1 reference

PubMed publication ID

22212587

1 reference